S-Adenosylmethionine Therapy for Non-Alcoholic Steatohepatitis

Status Completed

Clinical Trial Summary

The purpose of this study is to examine the effect of S-adenosylmethionine therapy in those patients with non-alcoholic liver disease in the form of steatohepatitis (NASH). This will be accomplished by development of a database of these patients, all of whom will have biopsy documented NASH. A placebo controlled trial will then examine the effect of S-adenosylmethionine over time on clinical outcome in these patients. It is expected that this agent will slow or halt the progression of this disease.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00108589
Study type	Interventional
Source	VA Office of Research and Development
Contact
Status	Completed
Phase	Phase 3
Start date	January 2004
Completion date	December 2006

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05738681` - Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial	Phase 2/Phase 3
Recruiting	`NCT05989958` - The Safety and Tolerability Study of HepaCure in Chinese Subjects With Acute-On-Chronic Liver Failure	Phase 1
Not yet recruiting	`NCT06395129` - Low Dead-space Injecting Equipment Distribution Program for People Who Inject Drugs in Low- and Middle-income Countries
Terminated	`NCT01443923` - Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV	Phase 4
Completed	`NCT00679692` - Evaluation the Growth Factors(IGF-1,IGFBP-3and HGH)in Patients With Chronic Liver Disease	N/A
Completed	`NCT00300209` - Manhattan HIV/Hepatology Brain Bank	N/A
Recruiting	`NCT05563961` - A Partial Randomized, Single-blind or Open-label, Dose-escalation With Multiple-dose Design Study to Evaluate the Pharmacokinetics of Acetaminophen and Its Toxic Metabolites With Panadol® and SafeTynadol® in Healthy Volunteers	N/A
Recruiting	`NCT05635266` - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Completed	`NCT00160407` - Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH)	Phase 4
Recruiting	`NCT03692897` - An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection
Completed	`NCT03509688` - The Curative Effect of Entecavir Combined Resveratrol on HBV patients-a Multi-center, Random, Open Clinical Trial	N/A
Recruiting	`NCT02275195` - Immune Cell Dysfunction in Severe Alcoholic Hepatitis
Completed	`NCT01740089` - Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C	Phase 2/Phase 3
Completed	`NCT00987337` - Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects	Phase 2
Completed	`NCT00929786` - Anti-tuberculosis (TB) Drug Levels and Hepatotoxicity	N/A
Completed	`NCT00564642` - Investigation of the Effect of N Acetylcysteine Against Anti-Tuberculosis Drugs Induced Liver Toxicity	N/A
Completed	`NCT00080236` - Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation	Phase 2
Recruiting	`NCT05719480` - A Bidirectional Study in Exploring the Dynamic Changes of Plasma and Urine Metabolites of Liver Cancer
Suspended	`NCT04306939` - Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study
Completed	`NCT03482388` - Crowdsourcing to Promote HBV and HCV Testing in China	N/A